EA201892499A1 - NEW PEPTIDES, COMBINATION OF PEPTIDES AS A TARGET AND MEANS FOR APPLICATION IN THE IMMUNOTHERAPY OF CANCER BUBBLE AND HOLANGIOCARCINOMA AND OTHER CANCER - Google Patents
NEW PEPTIDES, COMBINATION OF PEPTIDES AS A TARGET AND MEANS FOR APPLICATION IN THE IMMUNOTHERAPY OF CANCER BUBBLE AND HOLANGIOCARCINOMA AND OTHER CANCERInfo
- Publication number
- EA201892499A1 EA201892499A1 EA201892499A EA201892499A EA201892499A1 EA 201892499 A1 EA201892499 A1 EA 201892499A1 EA 201892499 A EA201892499 A EA 201892499A EA 201892499 A EA201892499 A EA 201892499A EA 201892499 A1 EA201892499 A1 EA 201892499A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- peptides
- cancer
- combination
- present
- immunotherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Настоящее изобретение относится к пептидам, белкам, нуклеиновым кислотам и клеткам для применения в иммунотерапевтических методах. В частности, настоящее изобретение относится к иммунотерапии рака. Настоящее изобретение относится далее к опухолеассоциированным пептидным эпитопам T-клеток, в отдельности или в комбинации с другими опухолеассоциированными пептидами, которые могут, например, служить в качестве активных фармацевтических ингредиентов вакцинных композиций, стимулирующих противоопухолевые иммунные ответы, или стимулировать T-клетки ex vivo с их перенесением в организм пациента. Пептиды, связанные с молекулами главного комплекса гистосовместимости (МНС), или пептиды в отдельности могут быть также мишенями антител, растворимых T-клеточных рецепторов и других связывающих молекул.The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to cancer immunotherapy. The present invention further relates to tumor-associated peptide T-cell epitopes, alone or in combination with other tumor-associated peptides, which may, for example, serve as active pharmaceutical ingredients of vaccine compositions that stimulate antitumor immune responses, or stimulate T-cells ex vivo with their transfer to the patient. Peptides linked to molecules of the major histocompatibility complex (MHC), or peptides individually, can also be targets for antibodies, soluble T-cell receptors and other binding molecules.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662341367P | 2016-05-25 | 2016-05-25 | |
PCT/EP2017/062334 WO2017202806A1 (en) | 2016-05-25 | 2017-05-23 | Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201892499A1 true EA201892499A1 (en) | 2019-04-30 |
Family
ID=65728674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892499A EA201892499A1 (en) | 2016-05-25 | 2017-05-23 | NEW PEPTIDES, COMBINATION OF PEPTIDES AS A TARGET AND MEANS FOR APPLICATION IN THE IMMUNOTHERAPY OF CANCER BUBBLE AND HOLANGIOCARCINOMA AND OTHER CANCER |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR110039A1 (en) |
EA (1) | EA201892499A1 (en) |
-
2017
- 2017-05-23 EA EA201892499A patent/EA201892499A1/en unknown
- 2017-05-24 AR ARP170101421A patent/AR110039A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR110039A1 (en) | 2019-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891116A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE USE OF SEVERAL CANCER TYPES IN IMMUNOTHERAPY | |
EA201891638A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN NHL IMMUNOTHERAPY AND OTHER CANCER TYPES | |
EA201891465A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN BREAST CANCER IMMUNOTHERAPY AND OTHER CANCER TYPES | |
EA201890635A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN IMMUNOTHERAPY OF SMALL CELLS OF LUNG AND OTHER CANCER SPECIES | |
EA201792632A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN THE IMMUNOTHERAPY OF OVAR CANCER AND OTHER CANCER | |
EA201890440A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN IMMUNOTHERAPY OF PROSTATE CANCER AND OTHER CANCER TYPES | |
EA201891074A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN CLL IMMUNOTHERAPY AND OTHER CANCER TYPES | |
EA201890027A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION OF EPITELIAL OVARIAN CANCER AND OTHER TYPE OF CANCER | |
EA201891699A2 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE APPLICATION IN IMMUNOTHERAPY OF SEVERAL TUMOR SPECIES | |
EA201891701A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE APPLICATION IN IMMUNOTHERAPY OF NON-SMALL CELL LUNG AND OTHER CANCER | |
EA201792484A1 (en) | NEW CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE OF MYELOMA AND OTHER CANCER IN IMMUNOTHERAPY | |
EA201891994A1 (en) | Uterus Cancer Treatment | |
EA201791853A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE APPLICATION IN THE IMMUNOTHERAPY OF CANCER OF THE REFERRAL GLAND AND OTHER TYPES OF CANCER | |
EA201891670A1 (en) | PEPTIDES, PEPTIDE COMBINATIONS AND CELL BASED MEDICATIONS FOR USING URINARY BLADDER AND OTHER CANCER IMMUNOTHERAPY | |
EA201792044A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN LUNG CANCER IMMUNOTHERAPY, INCLUDING NON-SMALL CELL LUNG CANCER AND OTHER CANCER SPECIES | |
EA201890560A1 (en) | NEW PEPTIDES, PEPTIDE COMBINATIONS AND FRAMEWORK FOR APPLICATION IN THE IMMUNOTHERAPEUTIC METHOD OF TREATING DIFFERENT CANCER TYPES | |
EA201792242A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES AND THEIR CARDS FOR USE IN COLORECTAL CARCINOMA AND OTHER CANCER IN IMMUNOTHERAPY | |
EA201791950A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES AND FRAMEWORK FOR APPLICATION IN IMMUNOTHERAPY OF KIDNEY CELL CARCINOMA (PAC) AND OTHER CANCER SPECIES | |
EA201992416A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN IMMUNOTHERAPY OF LEUKOSIS AND OTHER TYPES OF CANCER | |
EA201792531A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN IMMUNOTHERAPY AND METHODS OF OBTAINING FRAMEWORK FOR APPLICATION IN THE TREATMENT OF CANCER AND OTHER CANCER TYPES | |
EA201792671A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE USE OF EDUCATION AND OTHER SPECIES OF CANCER IN IMMUNOTHERAPY | |
EA201892333A1 (en) | IMMUNOTHERAPY OF MELANOMA AND OTHER CANCER SPECIES | |
EA201892159A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE USE OF AML AND OTHER CANCER IN IMMUNOTHERAPY | |
EA201991444A1 (en) | NEW PEPTIDES AND PEPTID COMBINATIONS FOR APPLICATION IN THE IMMUNOTHERAPY OF OVARIAN CANCER AND OTHER TYPES OF CANCER | |
EA201892499A1 (en) | NEW PEPTIDES, COMBINATION OF PEPTIDES AS A TARGET AND MEANS FOR APPLICATION IN THE IMMUNOTHERAPY OF CANCER BUBBLE AND HOLANGIOCARCINOMA AND OTHER CANCER |